Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -71.16% is 280% below its 5-year average of -18.72%, near the low end of its 5-year range (-71.16%–15.68%).
64.59% below its 12-month average of -43.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.18%.
RETURN ON ASSETS (ROA)
-71.16%
RETURN ON ASSETS (ROA) AVG TTM
-43.23%
RETURN ON ASSETS (ROA) AVG 3Y
-31.68%
RETURN ON ASSETS (ROA) AVG 5Y
-18.72%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-64.59%
CURRENT VS 3Y AVG
-124.64%
CURRENT VS 5Y AVG
-280.20%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-120.72%
vs the sector median at left
Atea Pharmaceuticals, Inc.
Market Cap
$405.51M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$402.49M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$404.30M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$407.02M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$408.21M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$410.03M
Return on Assets (ROA)
12.09%
TTM Avg
1.03%
3Y Avg
-6.34%
5Y Avg
-7.45%
Market Cap
$401.52M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$398.17M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$412.06M
Return on Assets (ROA)
-62.39%
TTM Avg
-45.13%
3Y Avg
-56.85%
5Y Avg
-56.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | $405.51M | -71.16% | -43.23% | -31.68% | -18.72% |
| Neurogene Inc. (NGNE)vs › | $402.49M | -45.47% | -26.84% | -30.13% | -31.02% |
| Rezolute, Inc. (RZLT)vs › | $404.30M | -68.75% | -55.58% | -51.15% | -46.76% |
| Myriad Genetics, Inc. (MYGN)vs › | $407.02M | -17.62% | -32.09% | -24.12% | -19.05% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | -41.33% | -54.52% | -54.52% | -54.52% |
| Strata Critical Medical, Inc. (SRTA)vs › | $410.03M | 12.09% | 1.03% | -6.34% | -7.45% |
| Carlsmed, Inc. (CARL)vs › | $401.52M | -30.75% | -34.79% | -68.11% | -68.11% |
| Shoulder Innovations, Inc. (SI)vs › | $398.17M | -23.05% | -30.00% | -27.77% | -27.77% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.06M | -62.39% | -45.13% | -56.85% | -56.85% |
| Prothena Corporation plc (PRTA)vs › | $418.30M | -14.54% | -48.52% | -33.40% | -26.00% |
ROA
-71.2%
ROE
-81.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -50.23% |
| 2024-12-31 | -36.24% |
| 2023-12-31 | -22.85% |
| 2022-12-31 | -17.39% |
| 2021-12-31 | 15.68% |
| 2020-12-31 | -1.27% |
| 2019-12-31 | -60.98% |
| 2018-12-31 | -26.00% |
